Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R)
Treatment for Burkitt lymphoma
Typical Dosage: Dose-adjusted based on nadir counts, intravenously
Effectiveness
85%
Safety Score
25%
Clinical Trials
3
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Dose-adjusted based on nadir counts, intravenously
Time to Effect
Within weeks of starting cycles
Treatment Duration
5-6 months (6-8 cycles)
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$70,000
Side Effect Mgmt:$70,000
Total Annual:$260,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$57,777/QALY
QALYs Gained
4.5
Outcome-Based Costs
Cost per Responder
$305,882.35
Cost per Remission
$346,666.67
Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R) Outcomes
for Burkitt lymphoma
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+75%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+90%
Febrile Neutropenia/Infection
+50%
Mucositis/Stomatitis
+55%
Nausea/Vomiting
+75%
Fatigue
+80%
Alopecia
+90%
Neurotoxicity (Vincristine-induced)
+30%
Cardiotoxicity (Doxorubicin-induced)
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R) in Burkitt lymphoma
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
NCT05453500ACTIVE NOT RECRUITINGPHASE2
32 participants
INTERVENTIONAL
Seattle, United States
Started: Mar 27, 2023
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
NCT06738368RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Seattle, United States
Started: May 8, 2026